vs

Side-by-side financial comparison of Energy Services of America CORP (ESOA) and Ultragenyx Pharmaceutical Inc. (RARE). Click either name above to swap in a different company.

Ultragenyx Pharmaceutical Inc. is the larger business by last-quarter revenue ($207.3M vs $114.1M, roughly 1.8× Energy Services of America CORP). On growth, Ultragenyx Pharmaceutical Inc. posted the faster year-over-year revenue change (25.9% vs 13.4%). Energy Services of America CORP produced more free cash flow last quarter ($16.8M vs $-100.8M). Over the past eight quarters, Ultragenyx Pharmaceutical Inc.'s revenue compounded faster (38.0% CAGR vs 26.7%).

Superior Energy Services is an American oil services company that operates as a holding company for a portfolio of oilfield equipment rentals and well oil and gas services brands.

Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.

ESOA vs RARE — Head-to-Head

Bigger by revenue
RARE
RARE
1.8× larger
RARE
$207.3M
$114.1M
ESOA
Growing faster (revenue YoY)
RARE
RARE
+12.5% gap
RARE
25.9%
13.4%
ESOA
More free cash flow
ESOA
ESOA
$117.5M more FCF
ESOA
$16.8M
$-100.8M
RARE
Faster 2-yr revenue CAGR
RARE
RARE
Annualised
RARE
38.0%
26.7%
ESOA

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
ESOA
ESOA
RARE
RARE
Revenue
$114.1M
$207.3M
Net Profit
$-128.6M
Gross Margin
12.3%
Operating Margin
4.3%
-54.7%
Net Margin
-62.0%
Revenue YoY
13.4%
25.9%
Net Profit YoY
3.5%
EPS (diluted)
$0.16
$-1.28

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ESOA
ESOA
RARE
RARE
Q4 25
$114.1M
$207.3M
Q3 25
$130.1M
$159.9M
Q2 25
$103.6M
$166.5M
Q1 25
$76.7M
$139.3M
Q4 24
$100.6M
$164.6M
Q3 24
$104.7M
$139.5M
Q2 24
$85.9M
$147.0M
Q1 24
$71.1M
$108.8M
Net Profit
ESOA
ESOA
RARE
RARE
Q4 25
$-128.6M
Q3 25
$-180.4M
Q2 25
$-115.0M
Q1 25
$-151.1M
Q4 24
$-133.2M
Q3 24
$-133.5M
Q2 24
$-131.6M
Q1 24
$-170.7M
Gross Margin
ESOA
ESOA
RARE
RARE
Q4 25
12.3%
Q3 25
12.6%
Q2 25
11.6%
Q1 25
0.1%
Q4 24
10.2%
Q3 24
16.8%
Q2 24
17.8%
Q1 24
8.8%
Operating Margin
ESOA
ESOA
RARE
RARE
Q4 25
4.3%
-54.7%
Q3 25
5.8%
-106.9%
Q2 25
3.1%
-64.8%
Q1 25
-10.6%
-102.6%
Q4 24
1.6%
-74.3%
Q3 24
8.4%
-94.6%
Q2 24
9.9%
-79.1%
Q1 24
-1.5%
-151.9%
Net Margin
ESOA
ESOA
RARE
RARE
Q4 25
-62.0%
Q3 25
-112.8%
Q2 25
-69.0%
Q1 25
-108.5%
Q4 24
-80.9%
Q3 24
-95.7%
Q2 24
-89.5%
Q1 24
-156.8%
EPS (diluted)
ESOA
ESOA
RARE
RARE
Q4 25
$0.16
$-1.28
Q3 25
$0.26
$-1.81
Q2 25
$0.12
$-1.17
Q1 25
$-0.41
$-1.57
Q4 24
$0.05
$-1.34
Q3 24
$0.40
$-1.40
Q2 24
$1.06
$-1.52
Q1 24
$-0.07
$-2.03

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ESOA
ESOA
RARE
RARE
Cash + ST InvestmentsLiquidity on hand
$16.7M
$421.0M
Total DebtLower is stronger
$62.0M
Stockholders' EquityBook value
$60.6M
$-80.0M
Total Assets
$201.0M
$1.5B
Debt / EquityLower = less leverage
1.02×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ESOA
ESOA
RARE
RARE
Q4 25
$16.7M
$421.0M
Q3 25
$12.2M
$202.5M
Q2 25
$15.3M
$176.3M
Q1 25
$9.9M
$127.1M
Q4 24
$20.3M
$174.0M
Q3 24
$12.9M
$150.6M
Q2 24
$14.5M
$480.7M
Q1 24
$12.1M
$112.3M
Total Debt
ESOA
ESOA
RARE
RARE
Q4 25
$62.0M
Q3 25
$72.2M
Q2 25
$59.1M
Q1 25
$50.7M
Q4 24
$59.6M
Q3 24
$33.9M
Q2 24
$31.9M
Q1 24
$45.7M
Stockholders' Equity
ESOA
ESOA
RARE
RARE
Q4 25
$60.6M
$-80.0M
Q3 25
$59.2M
$9.2M
Q2 25
$54.4M
$151.3M
Q1 25
$53.7M
$144.2M
Q4 24
$61.0M
$255.0M
Q3 24
$58.7M
$346.8M
Q2 24
$52.0M
$432.4M
Q1 24
$34.6M
$140.3M
Total Assets
ESOA
ESOA
RARE
RARE
Q4 25
$201.0M
$1.5B
Q3 25
$215.2M
$1.2B
Q2 25
$189.1M
$1.3B
Q1 25
$170.2M
$1.3B
Q4 24
$192.1M
$1.5B
Q3 24
$158.2M
$1.5B
Q2 24
$148.8M
$1.6B
Q1 24
$136.1M
$1.3B
Debt / Equity
ESOA
ESOA
RARE
RARE
Q4 25
1.02×
Q3 25
1.22×
Q2 25
1.09×
Q1 25
0.94×
Q4 24
0.98×
Q3 24
0.58×
Q2 24
0.61×
Q1 24
1.32×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ESOA
ESOA
RARE
RARE
Operating Cash FlowLast quarter
$18.8M
$-99.8M
Free Cash FlowOCF − Capex
$16.8M
$-100.8M
FCF MarginFCF / Revenue
14.7%
-48.6%
Capex IntensityCapex / Revenue
1.8%
0.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$3.1M
$-472.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ESOA
ESOA
RARE
RARE
Q4 25
$18.8M
$-99.8M
Q3 25
$-9.3M
$-91.4M
Q2 25
$3.4M
$-108.3M
Q1 25
$1.1M
$-166.5M
Q4 24
$8.9M
$-79.3M
Q3 24
$-847.5K
$-67.0M
Q2 24
$19.3M
$-77.0M
Q1 24
$-2.7M
$-190.7M
Free Cash Flow
ESOA
ESOA
RARE
RARE
Q4 25
$16.8M
$-100.8M
Q3 25
$-12.0M
$-92.7M
Q2 25
$-582.0K
$-110.7M
Q1 25
$-1.1M
$-167.8M
Q4 24
$6.0M
$-79.5M
Q3 24
$-2.9M
$-68.6M
Q2 24
$16.3M
$-79.0M
Q1 24
$-4.9M
$-193.9M
FCF Margin
ESOA
ESOA
RARE
RARE
Q4 25
14.7%
-48.6%
Q3 25
-9.3%
-58.0%
Q2 25
-0.6%
-66.5%
Q1 25
-1.4%
-120.5%
Q4 24
5.9%
-48.3%
Q3 24
-2.8%
-49.2%
Q2 24
18.9%
-53.7%
Q1 24
-6.9%
-178.2%
Capex Intensity
ESOA
ESOA
RARE
RARE
Q4 25
1.8%
0.5%
Q3 25
2.1%
0.8%
Q2 25
3.9%
1.5%
Q1 25
2.9%
1.0%
Q4 24
2.9%
0.1%
Q3 24
2.0%
1.2%
Q2 24
3.6%
1.4%
Q1 24
3.1%
3.0%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ESOA
ESOA

Electricals Mechanical And General$49.4M43%
Gas And Petroleum Transmission$24.1M21%
Cost Plus And TM Contracts$23.3M20%
Transferred At Point In Time$17.9M16%

RARE
RARE

Royalty$105.6M51%
Products$101.7M49%

Related Comparisons